We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Steroids Linked to Risk of Atrial Fibrillation

By HospiMedica staff writers
Posted on 02 Jun 2006
A new study shows that a daily dose of at least 7.5 mg of prednisone equivalents was associated with a sixfold increase in risk of new-onset atrial fibrillation. More...


Researchers form the Erasmus University Medical Center (Rotterdam, Holland) conducted a nested case-control study within the Rotterdam Study, an ongoing population-based cohort study of 7,893 residents of Ommoord, a Rotterdam suburb. All participants were 55 or older at baseline in 1990.

Participants underwent follow-up examinations every four to five years, and corticosteroid use was tracked by computerized pharmacy records. The study endpoint was atrial fibrillation, death, or the end of the study period (January 1, 2000). During the follow-up, the researchers identified 385 patients with new onset atrial fibrillation, who were included in the analysis. Those cases were compared with 6,365 controls.

High-dose corticosteroid use was associated with an odds ratio (OR) of 6.07 for atrial fibrillation whereas low-intermediate-dose use was not. Because patients taking high-dose corticosteroids had other risk factors for atrial fibrillation, the authors performed additional age- and sex-adjusted analysis, examining the effects among a high-dosage group, a high-dose asthma/ chronic obstructive pulmonary disease (COPD) group, and an "other disease” group.

They then divided the cases into two groups--those with zero to two risk factors for atrial fibrillation and those with three or more risk factors--and analyzed the data again. Using that risk-stratified model, they found that among patients with zero to two risk factors who took high-dose corticosteroids the OR was 7.09, while in those with three or more atrial fibrillation risk factors the OR was 6.09. The results were reported in the May 9, 2006, issue of the Archives of Internal Medicine.

Lead author Dr. Cornelis S. van der Hooft and colleagues concluded that patients on high-dose corticosteroid therapy should be closely monitored with both clinical examination and electrocardiogram (ECG) analysis before and after therapy. Such monitoring, they wrote, "could increase the chance to diagnose and treat this serious arrhythmia as early as possible.”



Related Links:
Erasmus University Medical Center

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.